This announcement is a separate document:
海通证券股份有限公司关于重庆智翔金泰生物制药股份有限公司2024年度持续督导半年度跟踪报告
Haitong Securities Co., Ltd.\'s 2024 continuous supervision semi-annual follow-up report on Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.